» Articles » PMID: 27366711

Prevalence and Severity of Disordered Mineral Metabolism in Patients with Chronic Kidney Disease: A Study from a Tertiary Care Hospital in India

Overview
Specialty Endocrinology
Date 2016 Jul 2
PMID 27366711
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Disordered mineral metabolism is common complications of chronic kidney disease (CKD). However, there are limited data on the pattern of these disturbances in Indian CKD population.

Materials And Methods: This was a prospective observational study of CKD-mineral and bone disorder (CKD-MBD) over a period of 3 years. The biochemical markers of CKD-MBD, namely, calcium, phosphorus, alkaline phosphatase, intact parathyroid hormone (iPTH), and 25-hydoxyvitamin Vitamin D3 (25OHD), were measured in newly diagnosed CKD Stage 3-5 and prevalent CKD Stage 5D adult patients.

Results: A total of 462 patients of CKD Stage 3-5D were studied. The frequency of various biochemical abnormalities was hypocalcemia (23.8%), hypercalcemia (5.4%), hypophosphatemia (2.8%), hyperphosphatemia (55.4%), raised alkaline phosphatase (56.9%), secondary hyperparathyroidism (82.7%), and hypoparathyroidism (1.5%). 25OHD was done in 335 (72.5%) patients and 90.4% were found to have Vitamin D deficiency. About 70.6% of the patients had iPTH levels were above kidney disease outcomes quality initiative (KDOQI) target range. Nondiabetic CKD as compared to diabetic CKD had a higher alkaline phosphatase (P = 0.016), a higher iPTH (P = 0.001) a higher proportion of patients with iPTH above KDOQI target range (P = 0.09), and an elevated alkaline phosphatase (P = 0.004). The 25OHD levels were suggestive of severe Vitamin D deficiency in 33.7%, Vitamin D deficiency in 45.4%, and Vitamin D insufficiency in 11.3% patients. There was a significant positive correlation between iPTH with alkaline phosphatase (r = 0.572, P = 0.001), creatinine (r = 0.424, P = 0.001), and phosphorus (r = 0.241, P = 0.001) and a significant negative correlation with hemoglobin (r = -0.325, 0.001), age (r = -0.169, P = 0.002), and 25OHD (r = -0.126, P = 0.021). On multivariate logistic regression analysis, an elevated alkaline phosphatase was a significant predictor of hyperparathyroidism (odds ratio 9.7, 95% confidence interval 4.9-19.2, P = 0.001).

Conclusions: There was a high prevalence of CKD-MBD in Indian CKD patients. CKD-MBD is more common and more severe and has an early onset as compared to the western populations.

Citing Articles

Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.

Elnaga A, Serag I, Alsaied M, Khalefa B, Rajput J, Ramadan S Int Urol Nephrol. 2024; .

PMID: 39702842 DOI: 10.1007/s11255-024-04316-x.


Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.

Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z Front Endocrinol (Lausanne). 2024; 15:1400891.

PMID: 38974573 PMC: 11224516. DOI: 10.3389/fendo.2024.1400891.


Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.

Macdougall I, Ponikowski P, Stack A, Wheeler D, Anker S, Butler J Clin J Am Soc Nephrol. 2023; 18(9):1124-1134.

PMID: 37382961 PMC: 10564367. DOI: 10.2215/CJN.0000000000000223.


Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials.

Rosano G, Kalantar-Zadeh K, Jankowska E ESC Heart Fail. 2023; 10(2):1294-1304.

PMID: 36722321 PMC: 10053364. DOI: 10.1002/ehf2.14286.


Prevalence and outcomes associated with hypocalcaemia and hypercalcaemia among pre-dialysis chronic kidney disease patients with mineral and bone disorder.

Yong M, Seng J, Tan Y, Wong J, How P Singapore Med J. 2022; 65(8):421-429.

PMID: 36453429 PMC: 11382823. DOI: 10.4103/singaporemedj.SMJ-2021-391.


References
1.
Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

2.
Danese M, Belozeroff V, Smirnakis K, Rothman K . Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3(5):1423-9. PMC: 2518803. DOI: 10.2215/CJN.01060308. View

3.
. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

4.
Wald R, Tentori F, Tighiouart H, Zager P, Miskulin D . Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis. 2007; 49(2):257-66. DOI: 10.1053/j.ajkd.2006.11.027. View

5.
. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View